Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

<p>BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers BDC-1001 administered to initial patients in Phase 2 dose-expansion cohorts REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/bolt-biotherapeutics-initiates-phase-2-clinical-studies-of-bdc-1001-in-patients-with-her2-positive-cancer/">Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>